Evidence map›Paper›PMID 42232606›Full record

ArticleOncology research2026

UCK2 Drives Lung Adenocarcinoma Progression and Immune Dysregulation via the RHEB/mTOR Signaling Axis.

Xiaolin Wei, Jing Guo, Chuntao Tao, Yong Bao, Li Yang, Hong Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xiaolin WeiDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Jing GuoDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Chuntao TaoDepartment of Biochemistry and Molecular Biology, College of Basic Medical Sciences, Chongqing Medical University, Chongqing, China.
Yong BaoDepartment of Respiratory Medicine, Sichuan Taikang Hospital, Chengdu, China.
Li YangDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Hong ChenDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital, Chongqing Medical University, Chongqing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Adenocarcinoma of LungLung NeoplasmsRas Homolog Enriched in Brain ProteinTOR Serine-Threonine KinasesUridine KinaseBiomarkers, TumorCell Line, TumorCell MovementCell ProliferationDisease ProgressionFemaleGene Expression Regulation, NeoplasticHumansMalePrognosisSignal TransductionBiomarkers, TumorMTOR protein, humanRas Homolog Enriched in Brain ProteinRHEB protein, humanTOR Serine-Threonine KinasesUCK2 protein, humanUridine Kinasedrug sensitivitylung adenocarcinoma (LUAD)prognostic biomarkerRHEB/mTOR signalingUridine-cytidine kinase 2 (UCK2)

Identifiers

PMID42232606
PMCPMC13223187

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.